These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 35976306)

  • 1. Neurologic adverse events of cancer immunotherapy.
    Brito MH
    Arq Neuropsiquiatr; 2022 May; 80(5 Suppl 1):270-280. PubMed ID: 35976306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
    Pan PC; Haggiagi A
    Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological complications of cancer immunotherapy.
    Roth P; Winklhofer S; Müller AMS; Dummer R; Mair MJ; Gramatzki D; Le Rhun E; Manz MG; Weller M; Preusser M
    Cancer Treat Rev; 2021 Jun; 97():102189. PubMed ID: 33872978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological updates: neurological complications of CAR-T therapy.
    Tallantyre EC; Evans NA; Parry-Jones J; Morgan MPG; Jones CH; Ingram W
    J Neurol; 2021 Apr; 268(4):1544-1554. PubMed ID: 33140239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
    Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
    J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological complications of immune checkpoint inhibitor cancer immunotherapy.
    Zivelonghi C; Zekeridou A
    J Neurol Sci; 2021 May; 424():117424. PubMed ID: 33812689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
    Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
    Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.
    Rahman MM; Behl T; Islam MR; Alam MN; Islam MM; Albarrati A; Albratty M; Meraya AM; Bungau SG
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors.
    Pensato U; Guarino M; Muccioli L
    Front Neurol; 2022; 13():936141. PubMed ID: 35928132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurologic Complications of Cancer Therapies.
    Lee EQ
    Curr Neurol Neurosci Rep; 2021 Nov; 21(12):66. PubMed ID: 34817688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurologic Toxicities of Cancer Immunotherapies: a Review.
    Harrison RA; Tummala S; de Groot J
    Curr Neurol Neurosci Rep; 2020 Jun; 20(7):27. PubMed ID: 32514633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sicca syndrome associated with immune checkpoint inhibitor therapy.
    Harris JA; Huang K; Miloslavsky E; Hanna GJ
    Oral Dis; 2022 Nov; 28(8):2083-2092. PubMed ID: 34379884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
    Perrinjaquet C; Desbaillets N; Hottinger AF
    Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
    Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
    Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update.
    Vogrig A; Muñiz-Castrillo S; Farina A; Honnorat J; Joubert B
    J Neurol; 2022 Mar; 269(3):1701-1714. PubMed ID: 34708250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
    Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
    J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer Drugs and the Nervous System.
    Santomasso BD
    Continuum (Minneap Minn); 2020 Jun; 26(3):732-764. PubMed ID: 32487905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Diagnosis and Treatment Recommendations for Adverse Reaction in the Nervous System Related to Immunocheckpoint Inhibitor].
    Shi J; Niu J; Shen D; Li Y; Liu M; Tan Y; Cui L; Guan Y; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):633-638. PubMed ID: 31650945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.